RVMD — Revolution Medicines Share News
0.000.00%
Last trade - 00:00- $40.57bn
- $37.66bn
Brief: CHMP Recommends Granting Marketing Authorisation For Rasonque For Metastatic Pancreatic Cancer In EU
Revolution Medicines wins EU committee backing for pancreatic cancer treatment (updated)
EMA recommends approval of Revolution's pancreatic cancer drug
Revolution Medicines falls on pancreatic cancer drug data concerns
Street View: Revolution's pancreatic cancer drug nod sparks a 'transformative' era
U.S. RESEARCH ROUNDUP-CrowdStrike, Nvidia, Macerich
U.S. STOCKS ON THE MOVE-Williams-Sonoma, Kraft Heinz, Evommune
Brief: Revolution Medicines Reports U.S. FDA Approves Its RASONQUE
U.S. STOCKS ON THE MOVE-Revolution Medicines, Abercrombie & Fitch, Williams-Sonoma
Brief: FDA Approves First In Class Targeted Therapy For Metastatic Pancreatic Cancer
Revolution Medicines rises after FDA approves pancreatic cancer drug
Revolution's lifesaving pancreatic cancer drug wins speedy FDA approval (updated)
US FDA approves Revolution Medicines' pancreatic cancer drug
Cullinan climbs as lung cancer drug meets late-stage trial goal
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
U.S. STOCKS ON THE MOVE-Duke Energy, Sea, Cardinal Health
Truist raises Revolution Medicines PT on lung cancer pipeline potential
Brief: BeOne Medicines And Revolution Medicines Announce Clinical Development And Regional Commercialization Collaboration